Now online in @CD_AACR: Eradicating Drug Tolerant Persister Cells in EGFR-Mutated NSCLC by Targeting TROP2 with CAR-T Cellular Therapy - by Simon Baldacci, @EJBrea, Francesco Facchinetti, @ESmithMDPhD, Pasi Jänne, @DavidBarbie8, and colleagues https://t.co/psE0fK7kPz @DanaFarber
Congratulations to Eric Smith, MD, PhD, @DanaFarber on receiving the Outstanding New Investigator Award from @ASGCTherapy. Smith will present on advancing CAR T cell therapy for cancer immunotherapy. #ASGCT2025
We’re getting ready to wrap up #AACR25 today, but not before congratulating @DanaFarber's Matthew Meyerson, MD, PhD, FAACR, @DrChoueiri and Alice T. Shaw, MD, PhD, once again for receiving @AACR 2025 Scientific Achievement Awards. @DanaFarber
➡️ https://t.co/eJzRT7DvnC
➡️Join our next BCDI meeting for exciting discussions on programmed cell removal from @mounicav07 @broadinstitute and NK-mediated targeting of tumor cells from @MichalSheffer@DanaFarber! Monday April 7th at 3PM on the Harvard Med Quad. https://t.co/uOJiL13B18
Thrilled to share our paper, "First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer".
A big thank you to Roman Shapiro, Rizwan Romee @romeerizwan, Glen Hanna @HeadNeckMD and all co-authors.
6/6 This study highlights the important considerations for the design of future clinical trials combining cellular therapy with checkpoint inhibition and the complexity of this combination.
5/6 and activation. On the other hand, ipilimumab was associated with reduced donor NK cell persistence, suggesting that this was mediated by the rapid recovery of CD8+ T cells, rejecting the donor cells via HLA mismatch
Promising mem-like NK cell study led by @Roma_Shap in MRD+ and or TP53mut AML undergoing RIC HCT..addressing a major unmet need. https://t.co/iO4nEnQWGJ
Incredibly proud of Linh and Isabel who worked as research assistants in the lab and now soon starting their graduate school at Brown and BU. #romeelab @MichalSheffer